Drug
Panitumumab
Panitumumab: highest development phase Post-Market, developed by Amgen, Dr. Reddy's. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Amgen, Dr. Reddy's
Trials
| Drug | Phase | Indication |
|---|---|---|
| Panitumumab NCT02301962 | Post-Market | Cancer |
| Panitumumab NCT00819780 | Phase 2 | Colon Cancer |
| Panitumumab NCT01305772 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck |
Latest
No recent events.
Follow Panitumumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.